lenalidomide has been researched along with gant 61 in 1 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (gant 61) | Trials (gant 61) | Recent Studies (post-2010) (gant 61) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 160 | 0 | 150 |
| Protein | Taxonomy | lenalidomide (IC50) | gant 61 (IC50) |
|---|---|---|---|
| Zinc finger protein GLI1 | Mus musculus (house mouse) | 5 | |
| Zinc finger protein GLI2 | Mus musculus (house mouse) | 5 | |
| Sonic hedgehog protein | Mus musculus (house mouse) | 5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, W; Li, J; Liu, X; Shi, J; Zhang, Z; Zhao, L; Zhou, Y | 1 |
1 review(s) available for lenalidomide and gant 61
| Article | Year |
|---|---|
A review on the treatment of multiple myeloma with small molecular agents in the past five years.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Deubiquitinating Enzymes; Drug Development; Drug Resistance; Histone Deacetylases; Humans; Ikaros Transcription Factor; Immunomodulating Agents; Models, Molecular; Morpholines; Multiple Myeloma; Phthalimides; Piperidones; Proteasome Inhibitors; Treatment Outcome; Ubiquitin-Protein Ligases | 2022 |